Findings from this phase 2 trial support further study of erlotinib as "an effective, acceptable cancer preventive agent for FAP-associated gastrointestinal polyposis," the study team says.
Cancer patients treated with the targeted agent need to be closely monitored for interstitial lung disease/pneumonitis as an adverse event, say researchers reporting a new analysis.
A study coordinated by Italian researchers investigated the prognostic performance of PREDICT in patients with early-stage HER2-positive breast cancer.
The agency has granted an accelerated approval for trastuzumab deruxtecan (Enhertu) to be used in patients with metastatic non–small cell lung cancer whose tumors have HER2 mutations.